Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2020; 26(3): 324-334
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.324
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.324
Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
Gaël Stéphane Roth, Mélodie Abousalihac, Thomas Decaens, Clinique Universitaire d’Hépato-Gastroentérologie et Oncologie Digestive, CHU Grenoble-Alpes, Grenoble 38043, France
Gaël Stéphane Roth, Yann Teyssier, Arnaud Seigneurin, Thomas Decaens, Faculté de Médicine, Université Grenoble-Alpes, Domaine de la Merci, La Tronche 38700, France
Gaël Stéphane Roth, Thomas Decaens, Institute for Advanced Biosciences - INSERM U1209/CNRS UMR 5309/Université Grenoble-Alpes, Site Santé - Allée des Alpes, La Tronche 38700, France
Yann Teyssier, Julien Ghelfi, Christian Sengel, Clinique Universitaire de Radiologie et Imagerie Médicale, CHU Grenoble-Alpes, Grenoble 38043, France
Arnaud Seigneurin, Département de Santé Publique - CHU Grenoble-Alpes, Grenoble 38043, France
Thomas Decaens, Department of Hepatology and Gastroenterology, Grenoble-Alpes University Hospital, Grenoble 38043, France
Author contributions: Roth GS and Decaens T contributed to study design, data collection, analyses, writing, and revision; Teyssier Y contributed to data collection and radiological independent analyses; Abousalihac A and Sengel C contributed to data collection; Seigneurin A contributed to statistics analyses; Ghelfi J contributed to writing and revision; Teyssier Y and Abousalihac M equally contributed to this work.
Institutional review board statement: Study ethics were approved by an independent institutional review board of CECIC Rhône-Alpes-Auvergne, Clermont-Ferrand.
Informed consent statement: Patients gave their written consent before TACE procedures. No specific consent statement was required regarding the retrospective analysis of data as they were anonymously used.
Conflict-of-interest statement: Authors did not declare any conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Thomas Decaens, MD, PhD, Full Professor, Department of Hepatology and Gastroenterology, Grenoble-Alpes University Hospital, BP 217, Cedex 09, Grenoble 38043, France. tdecaens@chu-grenoble.fr
Received: October 7, 2019
Peer-review started: October 7, 2019
First decision: November 10, 2019
Revised: December 13, 2019
Accepted: December 21, 2019
Article in press: December 21, 2019
Published online: January 21, 2020
Processing time: 100 Days and 22.2 Hours
Peer-review started: October 7, 2019
First decision: November 10, 2019
Revised: December 13, 2019
Accepted: December 21, 2019
Article in press: December 21, 2019
Published online: January 21, 2020
Processing time: 100 Days and 22.2 Hours
Core Tip
Core tip: Transarterial chemoembolization in the treatment of choice for intermediate stage hepatocellular carcinoma. Doxorubicin is the most used drug without any satisfying evidence of its superiority compared with other drugs. An increasing number of preclinical and early phase clinical studies suggest the superiority of idarubicin anti-tumor efficacy in transarterial chemoembolization. With the limits relative to retrospective analysis, this study shows that idarubicin represents an alternative to doxorubicin in the treatment of hepatocellular carcinoma with comparable efficacy and safety. It needs to be confirmed by randomized clinical trials.